Amplia Therapeutics Limited, a pharmaceutical company, engages in the development of focal adhesion kinase (FAK) inhibitors in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.20|
|52 Week High||AU$0.17|
|52 Week Low||AU$0.35|
|1 Month Change||0%|
|3 Month Change||-4.76%|
|1 Year Change||2.56%|
|3 Year Change||-28.57%|
|5 Year Change||-97.14%|
|Change since IPO||-90.00%|
Recent News & Updates
|ATX||AU Biotechs||AU Market|
Return vs Industry: ATX underperformed the Australian Biotechs industry which returned 3.7% over the past year.
Return vs Market: ATX underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: ATX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ATX's weekly volatility (10%) has been stable over the past year.
About the Company
Amplia Therapeutics Limited, a pharmaceutical company, engages in the development of focal adhesion kinase (FAK) inhibitors in Australia. The company is developing inhibiting drug candidates, including AMP886 and AMP945 for oncology and chronic fibrosis indications. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney.
Amplia Therapeutics Fundamentals Summary
|ATX fundamental statistics|
Is ATX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATX income statement (TTM)|
|Cost of Revenue||AU$312.01k|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.018|
|Net Profit Margin||-148.75%|
How did ATX perform over the long term?See historical performance and comparison
Is Amplia Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ATX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ATX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ATX is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: ATX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATX is good value based on its PB Ratio (2.4x) compared to the AU Biotechs industry average (4.9x).
How is Amplia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Amplia Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Amplia Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATX is currently unprofitable.
Growing Profit Margin: ATX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATX is unprofitable, but has reduced losses over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare ATX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).
Return on Equity
High ROE: ATX has a negative Return on Equity (-22.06%), as it is currently unprofitable.
How is Amplia Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ATX's short term assets (A$2.9M) exceed its short term liabilities (A$539.1K).
Long Term Liabilities: ATX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ATX is debt free.
Reducing Debt: ATX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ATX has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.6% each year.
What is Amplia Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Lambert (56 yo)
Dr. John Lambert, (B.Sc. (Hons), PhD GAICD, has been the Chief Executive Officer at Amplia Therapeutics Limited since June 24, 2019 and its Managing Director and Director since February 6, 2020. Dr. Lamber...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD320.60K) is about average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: ATX's management team is considered experienced (3.4 years average tenure).
Experienced Board: ATX's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ATX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.
Amplia Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Amplia Therapeutics Limited
- Ticker: ATX
- Exchange: ASX
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$24.964m
- Shares outstanding: 124.82m
- Website: https://www.ampliatx.com
- Amplia Therapeutics Limited
- 90 Collins Street
- Level 21
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 16:22|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.